Alcami has acquired a 37,000-square-foot facility in Research Triangle Park for $6.7 million, expanding the contract development and manufacturing organization’s analytical and development footprint in Durham, North Carolina.
The two-story building at 4620 Creekstone Drive will serve as a hub for Alcami’s growing advanced laboratory services and is expected to support rising demand for complex therapeutic programs, including biologics.
The acquisition builds on Alcami’s October announcement that it would pursue a major laboratory expansion at the Creekstone Drive site, with work scheduled for completion later this year. Alcami said the expanded labs will enhance its ability to support analytical and development work across biologics, peptides, proteins, oligonucleotides, and cell and gene therapy drug substances, broadening the company’s service capacity for clients developing next-generation therapies.
Alcami is already established in the RTP region with lab operations, sterile fill-finish manufacturing, and cGMP storage capabilities. The company said the added facility strengthens its ability to deliver integrated solutions that can help streamline drug development timelines while reducing supply chain risk through a U.S.-based network and expanded regional capacity.
The Durham expansion also follows Alcami’s recent qualification of a third sterile fill-finish line at its RTP campus. With that addition, Alcami said it now operates five qualified GMP-compliant sterile fill-finish lines across its network for clinical and commercial manufacturing, underscoring a broader effort to scale capabilities supporting customers from development through production and distribution.
Alcami, based in North Carolina, has more than 45 years of experience supporting pharmaceuticals and biologics and provides integrated lab services, drug product manufacturing, cGMP pharmaceutical storage, and related support services. The company is privately held and backed by GHO Capital, The Vistria Group, and Ampersand Capital Partners.
KEY QUOTE:
“This acquisition marks another milestone in our strategy to deliver innovative, scalable solutions for our clients in the growing area of biologics. By expanding our analytical lab capabilities in RTP, we’re able to support innovators in bringing life-changing therapies to patients faster and more reliably.”
Katie Schlipp, President, Lab Operations, Alcami
